Zacks: Analysts Anticipate Heron Therapeutics Inc (NASDAQ:HRTX) to Post -$0.61 Earnings Per Share

Brokerages expect Heron Therapeutics Inc (NASDAQ:HRTX) to post ($0.61) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Heron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.69). Heron Therapeutics reported earnings per share of ($0.49) during the same quarter last year, which would suggest a negative year over year growth rate of 24.5%. The business is expected to announce its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Heron Therapeutics will report full-year earnings of ($2.73) per share for the current year, with EPS estimates ranging from ($2.94) to ($2.48). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.63) per share, with EPS estimates ranging from ($2.15) to ($0.95). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. The firm had revenue of $36.66 million during the quarter, compared to analysts’ expectations of $31.04 million.

Several equities analysts recently issued reports on the stock. Evercore ISI reiterated a “buy” rating and issued a $75.00 target price on shares of Heron Therapeutics in a research note on Tuesday, August 13th. Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 target price on shares of Heron Therapeutics in a research note on Monday, August 5th. Northland Securities reiterated a “buy” rating and issued a $55.00 target price on shares of Heron Therapeutics in a research note on Monday, August 5th. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. Finally, Cowen reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, May 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $52.67.

Shares of HRTX traded up $0.39 during trading hours on Friday, hitting $18.39. The stock had a trading volume of 454,981 shares, compared to its average volume of 974,504. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.70 and a current ratio of 4.01. The firm has a 50-day moving average price of $17.88 and a 200 day moving average price of $21.29. Heron Therapeutics has a fifty-two week low of $15.68 and a fifty-two week high of $41.10. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -7.54 and a beta of 1.49.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Clearbridge Investments LLC lifted its holdings in Heron Therapeutics by 153.4% in the first quarter. Clearbridge Investments LLC now owns 2,180,577 shares of the biotechnology company’s stock valued at $53,293,000 after acquiring an additional 1,320,025 shares during the period. JPMorgan Chase & Co. lifted its holdings in Heron Therapeutics by 319.0% during the first quarter. JPMorgan Chase & Co. now owns 889,696 shares of the biotechnology company’s stock worth $21,744,000 after acquiring an additional 677,354 shares in the last quarter. Norges Bank bought a new position in Heron Therapeutics during the fourth quarter worth about $13,679,000. WS Management Lllp bought a new position in Heron Therapeutics during the first quarter worth about $11,174,000. Finally, C WorldWide Group Holding A S lifted its holdings in Heron Therapeutics by 178.5% during the second quarter. C WorldWide Group Holding A S now owns 702,069 shares of the biotechnology company’s stock worth $13,051,000 after acquiring an additional 450,000 shares in the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.